 Home > Active Ingredient News > Antitumor Therapy > Lancet Oncol: Adaptive de-escalation of radiotherapy based on recurrence risk after initial chemotherapy for cT1-2N1 breast cancer

Lancet Oncol: Adaptive de-escalation of radiotherapy based on recurrence risk after initial chemotherapy for cT1-2N1 breast cancer

 Last Update: 2022-08-19
 Source: Internet
 Author: User

Tags

sulfato de cobre

monoi de tahiti

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Primary chemotherapy for breast cancer presents a dilemma with adjuvant local radiotherapy because guidelines for local radiotherapy were originally based on the pathological findings of primary surger.

This prospective registry study included patients referred to one of 17 radiation oncology centres in the Netherlands between January 1, 2011 and January 1, 2015, who received initial chemotherapy and breast-grade axillary surgery for cT1- Patients with stage 2N1 breast cance.

838 patients were eligible for the 5-year follow-up analysis: 291 in the low-risk group, 370 in the intermediate-risk group, and 177 in the high-risk grou.

In conclusion, the 5-year locoregional recurrence rate of all breast cancer patients in this study was less than 4%, supporting the researchers' hypothesis that in patients with cT1-2N1 stage breast cancer receiving primary chemotherapy, recurrence based on locoregional Risk-reducing locoregional radiation doses are oncologically saf.

Original source:

Sabine R de Wild, et a.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Crocetin27876-94-4

CAS No.: 27876-94-4

$1-1.1/G FOB

Betulinic acid472-15-1

CAS No.: 472-15-1

$1-1.1/G FOB

1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane 53-19-0

CAS No.: 53-19-0

Pharmacy Grade

$100/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.